PE20160529A1 - Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas - Google Patents

Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas

Info

Publication number
PE20160529A1
PE20160529A1 PE2016000076A PE2016000076A PE20160529A1 PE 20160529 A1 PE20160529 A1 PE 20160529A1 PE 2016000076 A PE2016000076 A PE 2016000076A PE 2016000076 A PE2016000076 A PE 2016000076A PE 20160529 A1 PE20160529 A1 PE 20160529A1
Authority
PE
Peru
Prior art keywords
inhibitor
treatment
combination
hyperproliferative diseases
gdc
Prior art date
Application number
PE2016000076A
Other languages
English (en)
Inventor
Mark Merchant
Marcia Belvin
John Moffat
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20160529A1 publication Critical patent/PE20160529A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion proporciona combinaciones que comprenden un inhibidor de MEK tal como GDC-0973, GDC-0623, GSK-112 0212 (trametinib), AZD-6244 (selumetinib), etc; o una de sus sales farmaceuticamente aceptables y un inhibidor de ERK (tal como GDC-0994, [(S)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)piridin-2(1H)-ona]. Las combinaciones son particularmente utiles para tratar trastornos hiperproliferativos, tal como el cancer
PE2016000076A 2013-09-05 2014-09-04 Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas PE20160529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361874206P 2013-09-05 2013-09-05

Publications (1)

Publication Number Publication Date
PE20160529A1 true PE20160529A1 (es) 2016-05-21

Family

ID=51492945

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000076A PE20160529A1 (es) 2013-09-05 2014-09-04 Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas

Country Status (21)

Country Link
US (1) US9532987B2 (es)
EP (1) EP3041471A1 (es)
JP (2) JP2016531139A (es)
KR (1) KR20160048807A (es)
CN (1) CN105517548B (es)
AR (1) AR097556A1 (es)
AU (1) AU2014317119B2 (es)
CA (1) CA2916619A1 (es)
CL (1) CL2016000042A1 (es)
EA (1) EA034872B1 (es)
HK (1) HK1218072A1 (es)
IL (1) IL243251B (es)
MA (1) MA38827A1 (es)
MX (1) MX370417B (es)
PE (1) PE20160529A1 (es)
PH (1) PH12016500270A1 (es)
SG (1) SG11201600989VA (es)
TW (1) TW201605477A (es)
UA (1) UA120423C2 (es)
WO (1) WO2015032840A1 (es)
ZA (1) ZA201600091B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037423T2 (hu) * 2012-03-01 2018-08-28 Array Biopharma Inc Szerin/treonin kináz inhibitorok
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
WO2015103137A1 (en) * 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
WO2016162325A1 (en) 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
TN2018000119A1 (en) 2015-11-09 2019-10-04 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
JP2019518426A (ja) * 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法
AU2017316618A1 (en) * 2016-08-23 2019-02-07 Genentech, Inc. Combination therapy for the treatment of pancreatic cancer
CA3041245C (en) 2016-11-25 2022-12-06 Shine Biopharma Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
JP2019019094A (ja) * 2017-07-19 2019-02-07 学校法人福岡大学 変異ｋｒａｓ関連シグナル阻害用組成物
JP2020532982A (ja) 2017-09-08 2020-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2021007499A1 (en) * 2019-07-11 2021-01-14 Emory University Combination therapies for managing cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053523B (zh) 2005-10-07 2022-03-25 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
CA2660963A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
BRPI0714635A2 (pt) 2006-08-21 2013-06-18 Genentech Inc compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune
CA2672327A1 (en) 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
WO2008157179A2 (en) 2007-06-12 2008-12-24 Genentech, Inc. N-substituted azaindoles and methods of use
MX2010006800A (es) 2007-12-19 2010-10-05 Genentech Inc 5-anilinoimidazopiridinas y metodos de uso de las mismas.
KR20100101666A (ko) 2007-12-19 2010-09-17 제넨테크, 인크. ８-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도
CN101945875B (zh) 2007-12-21 2013-04-24 健泰科生物技术公司 氮杂吲嗪及其使用方法
US8492427B2 (en) 2008-07-01 2013-07-23 Genentech, Inc. Isoindolones derivatives as MEK kinase inhibitors and methods of use
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
JP2013502236A (ja) 2009-08-24 2013-01-24 ジェネンテック， インコーポレイテッド Ｋｒａｓ変異及びｒｔｋ発現レベルを検出することによるｂ−ｒａｆ阻害剤治療に対する細胞の感受性の決定
AU2010314287A1 (en) 2009-10-12 2012-05-03 F. Hoffmann-La Roche Ag Combinations of a PI3K inhibitor and a MEK inhibitor
BR112013012740A2 (pt) 2010-11-23 2016-09-13 Abbvie Inc sais e formas cristalinas de um agente que induz apoptose
RU2013143839A (ru) 2011-02-28 2015-04-10 Эррэй Биофарма Инк. Ингибиторы сериновых/треониновых киназ
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
HUE037423T2 (hu) 2012-03-01 2018-08-28 Array Biopharma Inc Szerin/treonin kináz inhibitorok
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN104363908B (zh) 2012-05-30 2017-12-22 霍夫曼-拉罗奇有限公司 吡咯烷基杂环类
EA033573B1 (ru) 2012-08-17 2019-11-06 Hoffmann La Roche Комбинированное лечение меланомы, включающее введение кобиметиниба и вемурафениба
CN105143200B (zh) 2012-08-27 2018-10-16 阵列生物制药公司 用于治疗过度增殖性疾病的丝氨酸/苏氨酸激酶抑制剂
CR20200237A (es) 2012-10-12 2020-07-26 Exelixis Inc Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer (diviisional 2015-0245)
RU2015114936A (ru) 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
MX370906B (es) 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
AU2015245743B2 (en) 2014-04-09 2020-09-24 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
CL2016000042A1 (es) 2016-08-05
IL243251B (en) 2019-02-28
AR097556A1 (es) 2016-03-23
KR20160048807A (ko) 2016-05-04
JP2019031517A (ja) 2019-02-28
EA034872B1 (ru) 2020-03-31
SG11201600989VA (en) 2016-03-30
CN105517548B (zh) 2020-01-21
EP3041471A1 (en) 2016-07-13
HK1218072A1 (zh) 2017-02-03
MX2016002857A (es) 2016-06-22
WO2015032840A1 (en) 2015-03-12
CN105517548A (zh) 2016-04-20
ZA201600091B (en) 2017-04-26
AU2014317119A1 (en) 2016-03-03
AU2014317119B2 (en) 2019-12-05
US9532987B2 (en) 2017-01-03
MX370417B (es) 2019-12-10
US20150111869A1 (en) 2015-04-23
CA2916619A1 (en) 2015-03-12
UA120423C2 (uk) 2019-12-10
EA201690513A1 (ru) 2016-07-29
TW201605477A (zh) 2016-02-16
MA38827A1 (fr) 2017-10-31
JP2016531139A (ja) 2016-10-06
PH12016500270A1 (en) 2016-05-16

Similar Documents

Publication Publication Date Title
PE20160529A1 (es) Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2019007256A (es) Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano.
CR20160036A (es) Inhibidores cristalinos de bromodominios
MX2016012573A (es) Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
BR112017024917A2 (pt) síntese de compostos heterocíclicos
MX2017013797A (es) Inhibidor de janus quinasa.
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
UY37205A (es) Inhibidores de bromodominios
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
AR103680A1 (es) Inhibidores selectivos de bace1
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
MX2014013855A (es) Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
TW201625535A (en) Inhibitors of histone demethylases
EP3492468A4 (en) HETEROCYCLIC COMPOUND AS A JAK INHIBITOR, SALTS AND THERAPEUTIC USE THEREOF